Gene-drug interactions in the melanocyte lineage and melanoma
Lead Research Organisation:
University of Edinburgh
Department Name: UNLISTED
Abstract
The aim of our work is to discover new therapeutic approaches and drug targets for melanoma. Melanoma is the most deadly form of skin cancer, and incidence continues to rise rapidly in the UK and Europe.
Recent advances in melanoma therapy often lead to regression of the cancer, but for most patients, the melanoma comes back. This suggests that while therapies can kill most of the cancer, there are some cells in the melanoma that are resistant to therapy. Our goal is to identify these different cells within melanoma, and develop new therapeutic approaches that can be used in combination with current therapy to eradicate the tumour.
We have developed a model system that enables us to genetically engineer zebrafish to develop melanomas that are similar to human melanomas. We use these animals to image the different cell types within melanoma, to screen for new drugs, and follow how the different cell populations within the cancers respond to new drugs at the single cell level. There are no other animal systems that allow us to do these studies at this resolution. We hope that these studies will help us to better understand how melanoma responds to drug treatment, and identify new vulnerabilities that we can use to target melanoma.
Recent advances in melanoma therapy often lead to regression of the cancer, but for most patients, the melanoma comes back. This suggests that while therapies can kill most of the cancer, there are some cells in the melanoma that are resistant to therapy. Our goal is to identify these different cells within melanoma, and develop new therapeutic approaches that can be used in combination with current therapy to eradicate the tumour.
We have developed a model system that enables us to genetically engineer zebrafish to develop melanomas that are similar to human melanomas. We use these animals to image the different cell types within melanoma, to screen for new drugs, and follow how the different cell populations within the cancers respond to new drugs at the single cell level. There are no other animal systems that allow us to do these studies at this resolution. We hope that these studies will help us to better understand how melanoma responds to drug treatment, and identify new vulnerabilities that we can use to target melanoma.
Technical Summary
My research goal is to develop new therapeutic approaches to treat melanoma. Our strategy is to interrogate the melanocyte lineage in zebrafish as a novel source of therapeutic targets and drug-leads that can target the diverse, heterogeneous subpopulations in melanoma.
As supported by an ERC Consolidator Award and a BBSRC funded screening facility, we perform phenotype-based small molecule screens on the zebrafish melanocyte lineage to identify new drugs that can target lineage specific vulnerabilities in melanoma.
Within the context of my core MRC Programme research, I now propose to translate one of the hit classes from our screen, the 5-NFNs, to target ALDHHigh subpopulations in cancer. In parallel, we will use zebrafish genetic technologies to discover and dissect the melanoma lineages that underpin the cancer cell subpopulations that drive disease progression and treatment failure. These efforts are further supported by a Melanoma Research Alliance-L’Oreal Team Award for Women in Science to identify and target dormant melanoma subpopulations.
The two main experimental aims of my MRC programme are:
Aim 1: To develop the potential of the 5-NFNs to target melanoma subpopulations and to reveal new 5-NFN synthetic lethal interactions.
Aim 2: To discover new melanocyte lineage and melanoma subpopulations in zebrafish and to test their role in melanoma progression and therapy.
We will use single cell sequencing, transcriptomics, and fluorescent reporter lines to identify and label heterogeneous cell populations in melanocyte development and in our melanoma models. Select chemical compounds from our screens will be tested in the context of targeting melanoma cell populations, and developed in pre-clinical models for drug-development.
As supported by an ERC Consolidator Award and a BBSRC funded screening facility, we perform phenotype-based small molecule screens on the zebrafish melanocyte lineage to identify new drugs that can target lineage specific vulnerabilities in melanoma.
Within the context of my core MRC Programme research, I now propose to translate one of the hit classes from our screen, the 5-NFNs, to target ALDHHigh subpopulations in cancer. In parallel, we will use zebrafish genetic technologies to discover and dissect the melanoma lineages that underpin the cancer cell subpopulations that drive disease progression and treatment failure. These efforts are further supported by a Melanoma Research Alliance-L’Oreal Team Award for Women in Science to identify and target dormant melanoma subpopulations.
The two main experimental aims of my MRC programme are:
Aim 1: To develop the potential of the 5-NFNs to target melanoma subpopulations and to reveal new 5-NFN synthetic lethal interactions.
Aim 2: To discover new melanocyte lineage and melanoma subpopulations in zebrafish and to test their role in melanoma progression and therapy.
We will use single cell sequencing, transcriptomics, and fluorescent reporter lines to identify and label heterogeneous cell populations in melanocyte development and in our melanoma models. Select chemical compounds from our screens will be tested in the context of targeting melanoma cell populations, and developed in pre-clinical models for drug-development.
Organisations
- University of Edinburgh (Lead Research Organisation)
- Francis Crick Institute (Collaboration)
- HARVARD UNIVERSITY (Collaboration)
- University of Manchester (Collaboration)
- Wellcome Trust (Collaboration)
- University of Montreal (Collaboration)
- London College (UCK) (Collaboration)
- Spanish National Cancer Research Center (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- Medical Research Council (MRC) (Collaboration)
People |
ORCID iD |
Publications
Brunsdon H
(2018)
Fishing for ancestry.
in eLife
Sarvi S
(2018)
ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells.
in Cell chemical biology
Zeng Z
(2018)
Notochord Injury Assays that Stimulate Transcriptional Responses in Zebrafish Larvae
in BIO-PROTOCOL
Al-Olabi L
(2018)
Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy.
in The Journal of clinical investigation
Bray TL
(2018)
Bright insights into palladium-triggered local chemotherapy.
in Chemical science
Lopez-Baez JC
(2018)
Wilms Tumor 1b defines a wound-specific sheath cell subpopulation associated with notochord repair.
in eLife
Ngeow KC
(2018)
BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.
in Proceedings of the National Academy of Sciences of the United States of America
Patton EE
(2019)
Spotlight on zebrafish: the next wave of translational research.
in Disease models & mechanisms
Camargo-Sosa K
(2019)
Endothelin receptor Aa regulates proliferation and differentiation of Erb-dependent pigment progenitors in zebrafish.
in PLoS genetics
Related Projects
| Project Reference | Relationship | Related To | Start | End | Award Value |
|---|---|---|---|---|---|
| MC_UU_00007/1 | 01/04/2018 | 31/03/2023 | £662,000 | ||
| MC_UU_00007/2 | Transfer | MC_UU_00007/1 | 01/04/2018 | 31/03/2023 | £3,730,000 |
| MC_UU_00007/3 | Transfer | MC_UU_00007/2 | 01/04/2018 | 31/05/2022 | £3,053,000 |
| MC_UU_00007/4 | Transfer | MC_UU_00007/3 | 01/04/2018 | 31/03/2023 | £1,772,000 |
| MC_UU_00007/5 | Transfer | MC_UU_00007/4 | 01/04/2018 | 31/03/2023 | £4,524,000 |
| MC_UU_00007/6 | Transfer | MC_UU_00007/5 | 01/04/2018 | 31/03/2023 | £2,878,000 |
| MC_UU_00007/7 | Transfer | MC_UU_00007/6 | 01/04/2018 | 31/03/2023 | £2,829,000 |
| MC_UU_00007/8 | Transfer | MC_UU_00007/7 | 01/04/2018 | 31/12/2022 | £4,072,000 |
| MC_UU_00007/9 | Transfer | MC_UU_00007/8 | 01/04/2018 | 31/03/2023 | £3,137,000 |
| MC_UU_00007/10 | Transfer | MC_UU_00007/9 | 01/04/2018 | 31/03/2023 | £6,948,000 |
| MC_UU_00007/11 | Transfer | MC_UU_00007/10 | 01/04/2018 | 31/03/2023 | £2,421,000 |
| MC_UU_00007/12 | Transfer | MC_UU_00007/11 | 01/04/2018 | 31/03/2023 | £1,205,000 |
| MC_UU_00007/13 | Transfer | MC_UU_00007/12 | 01/04/2018 | 31/03/2023 | £1,174,000 |
| MC_UU_00007/14 | Transfer | MC_UU_00007/13 | 01/04/2018 | 31/03/2023 | £1,838,000 |
| MC_UU_00007/15 | Transfer | MC_UU_00007/14 | 01/04/2018 | 31/03/2023 | £2,551,000 |
| MC_UU_00007/16 | Transfer | MC_UU_00007/15 | 01/04/2018 | 31/03/2023 | £1,496,000 |
| MC_UU_00007/17 | Transfer | MC_UU_00007/16 | 01/04/2018 | 31/03/2023 | £1,886,000 |
| Description | Accelerating the preclinical development of ROS-generating ALDH1-targeted suicide inhibitors for cancer treatment |
| Amount | £98,418 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2023 |
| End | 01/2024 |
| Description | Cellular barcoding to define melanoma drug resistance and cell of origin |
| Amount | $900,000 (USD) |
| Organisation | Melanoma Research Alliance |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 09/2022 |
| End | 08/2025 |
| Description | MRC Human Genetics Unit QQR |
| Amount | £3,200,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2023 |
| End | 03/2028 |
| Description | Targeting persister cell states that drive drug resistance and metastasis. |
| Amount | $900,000 (USD) |
| Funding ID | 687306 |
| Organisation | Melanoma Research Alliance |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 10/2020 |
| End | 09/2023 |
| Title | CFC-zebrafish |
| Description | We have developed an assay to test the activity of cardio-facio-cutaneous alleles, and to test the effects of specific clinically active drugs on restoring their "normal" activity |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2009 |
| Provided To Others? | Yes |
| Impact | Publication -- Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Anastasaki C, Estep AL, Marais R, Rauen KA, Patton EE. Hum Mol Genet. 2009 Jul 15;18(14):2543-54. Epub 2009 Apr 17. PMID: 19376813 [PubMed - indexed for MEDLINE] Anastasaki C, Rauen KA, Patton EE. Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish. Dis Model Mech. 2012 Jul;5(4):546-52. |
| URL | http://europepmc.org/abstract/MED/19376813 |
| Title | CRISPR-Cas9 zebrafish |
| Description | Developing gene editing techniques in zebrafish |
| Type Of Material | Model of mechanisms or symptoms - non-mammalian in vivo |
| Year Produced | 2019 |
| Provided To Others? | No |
| Impact | It helps us look at genetic mutations in zebrafish |
| Title | Drug Pellets |
| Description | https://doi.org/10.1101/2021.12.21.473492 Zebrafish embryos are widely used for drug-discovery however administering drugs to adult zebrafish is limited by current protocols that can cause stress. Here, we develop a drug formulation and administration method for adult zebrafish by producing food-based drug pellets which are consumed voluntarily. We apply this to zebrafish with BRAF-mutant melanoma, a model that has significantly advanced our understanding of melanoma progression, but not of drug resistance due to the limitations of current treatment methods. Short-term, precise, and daily dosing with drug-pellets made with the BRAFV600E inhibitor, vemurafenib, led to tumour regression. On-target drug efficacy was determined by phospho-ERK staining. Continued drug treatment led to the emergence, for the first time in zebrafish, of acquired drug resistance and melanoma relapse, modelling the responses seen in melanoma patients. This method presents a controlled, non-invasive approach that permits long-term drug studies, and can be widely applied to any adult zebrafish model. |
| Type Of Material | Model of mechanisms or symptoms - non-mammalian in vivo |
| Year Produced | 2021 |
| Provided To Others? | Yes |
| Impact | We have shared this protocol with many labs. This is important for the 3Rs and for adult zebrafish drug discovery. |
| URL | https://doi.org/10.1101/2021.12.21.473492 |
| Title | PRL3 mutant |
| Description | We have developed an important mutant line for our research in a gene called PRL3 in zebrafish |
| Type Of Material | Model of mechanisms or symptoms - non-mammalian in vivo |
| Provided To Others? | No |
| Impact | This will be critical to understand the role of PRL3 in an animal system, especially in melanocyte regeneration. It is currently unpublished. |
| Title | Small molecule |
| Description | a small molecule that causes a specific developmental phenotype (kills developing and differentiated melanocytes) |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | n/a considering for patent |
| Title | Tfap2b specifies an embryonic melanocyte stem cell that retains adult multifate potential |
| Description | scRNA-seq data to identify the melanocyte stem cell in zebrafish development |
| Type Of Material | Database/Collection of data |
| Year Produced | 2021 |
| Provided To Others? | Yes |
| Impact | Others are already using this data, and citing the paper |
| URL | https://www.cell.com/cell-reports/pdfExtended/S2211-1247(21)01743-5 |
| Title | Zebrafish MITF-Low Melanoma Subtype Models Reveal Transcriptional Subclusters and MITF-Independent Residual Disease |
| Description | RNA-seq of zebrafish melanomas scRNA-seq of melanoma cells |
| Type Of Material | Database/Collection of data |
| Year Produced | 2019 |
| Provided To Others? | Yes |
| Impact | Others have used these in publications (e.g. Elife) |
| URL | https://pubmed.ncbi.nlm.nih.gov/31582381/ |
| Description | CLOVE |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collabortion to model CLOVE syndrome in zebrafish |
| Collaborator Contribution | We have not begun yet, but we have had multiple interactions with the charity funder |
| Impact | At this stage, the funding has been agreed in principle, and we need to submit formal application to the Board |
| Start Year | 2021 |
| Description | CP/TC |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Human Genetics Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are using single cell analysis to study the melanocyte stem cell lineage |
| Collaborator Contribution | Concepts and helping with analysis |
| Impact | An eLIFE paper |
| Start Year | 2017 |
| Description | CS/ALDH |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | New collaboration with team in UK to examine function of ALDH in cells |
| Collaborator Contribution | We are sharing chemical compounds and sturctures |
| Impact | It is too early, but we are starting by testing some of their pre-drug leads in our models. |
| Start Year | 2018 |
| Description | Congential nevi application |
| Organisation | Francis Crick Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I am the leader of the team, and we are preparing a Wellcome Team Award |
| Collaborator Contribution | A team award group to apply for funding for congenital nevi cell of origin study |
| Impact | none yet, but grant in progress |
| Start Year | 2021 |
| Description | MRA Barcoding team |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | New collaborative grant, that has reached triage stage. Using bar codes to follow cell of origin in melanoma in zebrafish and in patient autopsies. |
| Collaborator Contribution | So far, we have written an application, and shared our new protocols. |
| Impact | None yet, but an application has been submitted |
| Start Year | 2021 |
| Description | MS/NFN |
| Organisation | Spanish National Cancer Research Center |
| Country | Spain |
| Sector | Public |
| PI Contribution | We are part of a team science award for women in science. We are studying metastasis and tumour cell dormancy. |
| Collaborator Contribution | We submitted a joint proposal that was successfully funded. We are currently sharing resources and ideas about tumour cell dormancy in melanoma. |
| Impact | £1million grant for women in science, with 5 partners - 3 in the USA, 1 Spain and 1 UK In addition to our science, we are trying bring awareness to women in science and to help shape the culture surrounding these issues. |
| Start Year | 2016 |
| Description | MT Drop out screen |
| Organisation | University of Montreal |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | This is a new collaboration to do a gene-drug screen (drop out screen) to determine drug mechanism of action. |
| Collaborator Contribution | This is a new collaboration - we will be sending our MRC postdoc to Montreal to learn how to do the technique, and hopefully bring some of the technology back to the UK. |
| Impact | This is a new collaboration and we do not have outputs at this stage. |
| Start Year | 2016 |
| Description | MT/Small molecule screening |
| Organisation | Wellcome Trust |
| Department | Wellcome Trust Centre for Cell Biology |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Mike Tyers: Small molecules of interest that are identified in zebrafish are screened in yeast to identify target pathways. |
| Collaborator Contribution | Publications (please see list attached) |
| Impact | Three manuscripts (one in review; two published, below) Differentiated melanocyte cell division occurs in vivo and is promoted by mutations in Mitf. Taylor KL, Lister JA, Zeng Z, Ishizaki H, Anderson C, Kelsh RN, Jackson IJ, Patton EE. Development. 2011 Aug;138(16):3579-89. Epub 2011 Jul 19. Combined zebrafish-yeast chemical-genetic screens reveal gene-copper-nutrition interactions that modulate melanocyte pigmentation. Ishizaki H, Spitzer M, Wildenhain J, Anastasaki C, Zeng Z, Dolma S, Shaw M, Madsen E, Gitlin J, Marais R, Tyers M, Patton EE. Dis Model Mech. 2010 Sep-Oct;3(9-10):639-51. Epub 2010 Aug 16. |
| Start Year | 2006 |
| Description | SS/NFN to clinic |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are looking into getting the NFNs into clinical trial |
| Collaborator Contribution | We have just started this collaboration. |
| Impact | clinical |
| Start Year | 2020 |
| Description | VK Mosaic syndromes |
| Organisation | London College (UCK) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We developed a zebrafish model to validate a new disease gene found in children with giant congenital nevi. |
| Collaborator Contribution | They identified new disease genes in children that cause giant congenital nevi. |
| Impact | Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis. Thomas AC, Zeng Z, Rivière JB, O'Shaughnessy R, Al-Olabi L, St-Onge J, Atherton DJ, Aubert H, Bagazgoitia L, Barbarot S, Bourrat E, Chiaverini C, Chong WK, Duffourd Y, Glover M, Groesser L, Hadj-Rabia S, Hamm H, Happle R, Mushtaq I, Lacour JP, Waelchli R, Wobser M, Vabres P, Patton EE, Kinsler VA. |
| Start Year | 2014 |
| Title | WT1 antibodies |
| Description | WT1 antibodies are currently beginning the licensing process with Cambridge Research Biochemicals |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | |
| Licensed | No |
| Impact | Still in development |
| Title | Early stages of discussion of clinical trial |
| Description | We are looking at NFNs as a clinical intervention for cancer following initial treatment |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2020 |
| Development Status | Under active development/distribution |
| Impact | N/A |
| Description | Conference Organizer |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Conference Organising Committee Strategic Conference for Zebrafish Investigators, Asilomar, California. 01-2019 Conference Organizing committee Society for Melanoma Research Conference, Manchester 10-2018 Conference Organizing committee NCRI Cancer Conference, Glasgow 10-2018 |
| Year(s) Of Engagement Activity | 2018,2019 |
| Description | Genes and Cancer meeting in Cambridge |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Scientific organizer for Genes and Cancer, Cambridge |
| Year(s) Of Engagement Activity | 2019 |
| Description | Invited PI to Postdoc talks at ZDMS |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Invited PI for talks at ZDMS, Boston |
| Year(s) Of Engagement Activity | 2019 |
| Description | Invited Speaker Royal Society of Biology: 23rd Annual Meeting for Biology Teachers, Edinburgh Scottish High School Teachers 05-2018 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation to school teachers about my science, very good response (informally) |
| Year(s) Of Engagement Activity | 2018 |
| Description | Invited speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited Speaker The European Melanoma Workshop, Sestri Levente, Italy 06-2017 Invited Speaker The Wistar Institute, Philadelphia, USA 06-2017 Invited Speaker Human Giant Nevus session, International Pigment Cell Conference, Colorado, USA 08-2017 Invited Speaker The Boston Zebrafish Workshop, Harvard Medical School, USA 10-2017 Invited Speaker International Melanoma Working Group, Edinburgh 03-2018 Invited Speaker Non-Mammalian Models Session, International Pigment Cell Conference, Colorado, USA 08-2017 Invited Speaker University of Toronto, Careers for PhD and postdoc conference 06-2018 Invited Speaker University College London Autumn 2018 Invited Speaker Blizard Institute, London 07-2018 Invited Speaker European Melanoma Workshop, Israel 04-2018 Invited Speaker Montagna Symposium of the Biology of Skin and Pan-American Society for Pigment Cell Research, Gleneden Beach, Oregon, USA 10-2018 Selected Speaker 11th Zebrafish Disease Models Conference, Leiden, July 2018 07-2018 Selected Speaker Society for Melanoma Research, Brisbane, Australia November 2017 11-2017 |
| Year(s) Of Engagement Activity | 2017,2018,2019 |
| Description | NCRI careers |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Careers in Science workshop in Glasgow at the NCRI |
| Year(s) Of Engagement Activity | 2019 |
| Description | NCRI scientific panel |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Committee for the NCRI scientific panel |
| Year(s) Of Engagement Activity | 2019 |
| Description | Open day IGMM talk |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Open Day lecture on our science (melanoma genetics) |
| Year(s) Of Engagement Activity | 2018 |
| Description | Patient Group Workshop |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Speaker at the MRA Patient Forumn |
| Year(s) Of Engagement Activity | 2020 |
| Description | Royal Society of Biology: Annual Meeting for Biology Teachers (Keynote) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Keynote Speaker May 2018 (Keynote) Royal Society of Biology: Annual Meeting for Biology Teachers |
| Year(s) Of Engagement Activity | 2019 |
| Description | School visit |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Was invited to the graduation of the highschool students and gave a brief presentation about science |
| Year(s) Of Engagement Activity | 2019 |
| Description | Shining a Light on Cancer - Living with Melanoma, Public-patient event. IGC Feb. 2021 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | Speaker at a Patient-Public event |
| Year(s) Of Engagement Activity | 2021 |
| Description | Talk at Sick Kids, Toronto |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | Invited speaker to Sick Kids, Toronto |
| Year(s) Of Engagement Activity | 2019 |
| Description | Workshop organizer |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Organizer and Leader Drug Discovery Research Interest Group, 10th Zebrafish Disease Models Conference, San Diego, USA 07-2017 Organizer and Leader Women in Science Session, 10th Zebrafish Disease Models Conference, San Diego, USA 07-2017 Organizer and Leader Mentoring workshop Women in Science Workshop 11th Zebrafish Disease Models Conference, Leiden 07-2018 |
| Year(s) Of Engagement Activity | 2018 |
| Description | invited session chair |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited Session Chair Melanoma Session, NCRI Cancer Conference, Glasgow 10-2018 Invited Session Chair 10th Zebrafish Disease Models Conference, San Diego, USA 07-2017 Invited Session Chair Non-Mammalian Models Session, International Pigment Cell Conference, Colorado, USA 08-2017 |
| Year(s) Of Engagement Activity | 2018,2019 |